Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06922084 · ClinicalTrials.gov registry record · Phase 4
A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects
A Phase 4 study of Cataract, sponsored by Berkeley Eye Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 320
- Enrollment target
- 2
- Study locations
NCT06922084: Recruiting Phase 4 study of Cataract, sponsored by Berkeley Eye Center.
NCT06922084 is a Phase 4 study of Cataract that is actively recruiting participants, run by Berkeley Eye Center. The registered enrollment target is 320 participants, above the 225-participant average among 83 other Cataract trials with a reported enrollment target (42% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06922084, a Phase 4 study of Cataract, is actively recruiting participants, sponsored by Berkeley Eye Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 320 participants
- Enrollment target
- 2
- Study locations
Study Summary
Prospective, randomized, multicenter, multi-arm, subject and vision-assessor-masked, two stage study with Stage 1 as a three-arm initial enrollment period, followed by Stage 2 as a head-to-head study refined based on the Stage 1 data.
Conditions Studied
Interventions
- DEVICE Clareon PanOptix
- DRUG Clareon PanOptix PRO
- DRUG Mix-and-Match PanOptix/Vivity
Study Locations (2)
Pennsylvania
- Shafer Vision Institute - Plymouth Meeting
Texas
- Berkeley Eye Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2025-03-17 |
| Est. Completion | 2026-04 |
| Phase | Phase 4 |
What NCT06922084 shows while recruiting
NCT06922084 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 225-participant average among 83 other Cataract trials with a reported enrollment target (42% higher).
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 3 interventions - of which Clareon PanOptix is the first listed.
NCT06922084 reports a single indexed study location in Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT06922084 about?
NCT06922084 is a clinical study titled "A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects". Prospective, randomized, multicenter, multi-arm, subject and vision-assessor-masked, two stage study with Stage 1 as a three-arm initial enrollment period, followed by Stage 2 as a head-to-head study refined based on the Stage 1 data.
What is the current status of trial NCT06922084?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 320 participants. The study started on 2025-03-17. Estimated completion is 2026-04.
What conditions does trial NCT06922084 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT06922084?
The interventions under investigation include: Clareon PanOptix (DEVICE), Clareon PanOptix PRO (DRUG), Mix-and-Match PanOptix/Vivity (DRUG).
Who is sponsoring clinical trial NCT06922084?
This trial is sponsored by Berkeley Eye Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06922084 being conducted?
This trial has 2 study locations across Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06922084's enrollment target sits among peer trials
320 16th of 83 higher than 68 of 83 other Cataract trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
RECRUITING · Phase 4
-
Evaluation of a Monofocal Intraocular Lens
RECRUITING · Phase 4
-
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
RECRUITING · Phase 4
-
Odyssey Evaluation in Post LASIK Patients
RECRUITING · Phase 4
-
Dropless vs. Standard Drops Contralateral Eye Study
COMPLETED · Phase 4
-
Evaluation of Effective Lens Position With a Uniplanar Bi-aspheric IOL
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI